© 2024 SEISMIC TX. ALL RIGHTS RESERVED.
Watertown, Mass., September 30, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the company’s participation in three upcoming scientific and medical conferences, presenting on Seismic’s emerging pipeline of novel therapeutics to treat rare and prevalent autoimmune diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery.
Details of Seismic’s presentations and poster sessions are as follows:
October 3-4: Biologics US, San Diego, CA
Presentation Title: Structure empowered IMPACT platform in the discovery & development of Immunoglobulin Sculpting (IgSc) enzyme & Dual-cell Bidirectional (DcB) antibody drugs for immunological diseases
Session: Track 1: Computational Tools, AI/ML-Guided Engineering
Date: Friday, October 4
Time: 2:15 p.m. PT
Presenter: Yi Xing, PhD, Senior Director, Head of Structural Biology
October 15-18: Myasthenia Gravis Foundation of America Scientific Session at American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, Savannah, GA
Presentation Title: Preclinical pharmacology of S-1117, a novel engineered Fc-fused IgG cleaving enzyme, for chronic treatment of autoantibody-mediated diseases including Myasthenia Gravis
Session: Therapeutics
Date: Tuesday, October 15
Time: 10:10 a.m. ET
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine
October 15-18: CHI Immunogenicity & Bioassay Summit, Washington, DC
Presentation Title: Machine learning for deimmunization and multi-objective optimization of biologics
Session: Immunogenicity Prediction & Control – Deimmunization, Developability, and Machine Learning
Date: Friday, October 18
Time: 3:35 p.m. ET
Presenter: Ryan Peckner, PhD, Director, Head of Machine Learning
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
This links to an external website.